Research will focus on developing new treatments for inflammatory bowel disease (IBD)
REHOVOT, Israel, April 13, 2022 /PRNewswire/ — Biomica Ltd. (Biomica), an emerging biopharmaceutical company developing innovative microbiome-based therapies and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it has signed a collaboration agreement with Sheba Medical Center (Sheba) in Tel Aviv, Israela hospital ranked by Newsweek magazine among the 10 best in the world in 2022.
As part of the joint work, Biomica and Sheba’s Microbiome Innovation Center, led by Dr. Yael Haberman, will perform deep sequencing and high-resolution microbiome analysis of samples from patients with inflammatory bowel disease (IBD). This analysis will identify potential profiles, biomarkers and therapeutic entities to better understand the human microbiome in patients with IBD. Based on the new discoveries expected to emerge from these joint studies, Biomica’s goal is to expand its expertise in this area, strengthening its ability to develop new therapies, addressing unmet medical needs and providing better care for patients with IBD.
IBD includes conditions such as ulcerative colitis and Crohn’s disease, which are chronic, debilitating, non-infectious, inflammatory diseases of the digestive tract. However, despite the recent introduction of new modalities and therapies, many patients do not respond well and the response of others may diminish over time.. The global IBD treatment market size has been valued at $19.2 billion in 2020.
dr. Yael Haberman at Sheba Medical Center, said“I look forward to our collaboration with Biomica, a pioneer in the field of IBD and a developer of new therapies based on the human microbiome. I believe our work together has great potential and I hope it will lead to better outcomes for people with IBD.”
Dr. Elran Haber, CEO of Biomica, said“I am very pleased today to launch this joint research effort between one of the largest hospitals in the world, Sheba Medical Center, and Biomica. Our goal is for the results of this study to be highly complementary to previous work. from Biomica on IBD, and advancing our ability to identify and utilize specific entities in the microbiome, providing improved treatments for this devastating disease. We see great potential in this collaboration with Dr. Haberman and hope that this will pave the way for further joint studies focused on improving patient care in IBD.”
As previously announced in November 2021Biomica has announced positive preclinical results in its IBD program following the evaluation of its product candidate BMC333, in a model of DSS-induced colitis. These results demonstrated the ability of BMC333 to significantly reduce intestinal tissue damage resulting from inflammation. Biomica expects to begin large-scale development processes for BMC333 in 2022, with a view to production of a first clinical batch.
BMC333 Live Bacterial Products (LBP), an optimized combination of four of the strains originally present in BMC321 and BMC322. All are rationally designed consortia designed to restore the diversity and specific functionality of a microbial community with individually selected cultured bacteria.
BMC333 is composed of bacterial strains selected for their multiple desired functions to achieve maximum functional activity with only 4 bacterial strains. These LBPs aim to achieve robust immune modulation through several underlying and complementary modes of action.
About Sheba Medical Center:
The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer generates global impact through its medical care, research and healthcare transformation. Sheba Health City has an acute care hospital, a rehabilitation hospital, research and innovation centers, a medical simulation center and a disaster response center. disaster on a full campus in central Israel. An academic teaching hospital affiliated with Tel Aviv University’s Sackler School of Medicine, Sheba is shaping the future of healthcare by training the next generation of healthcare providers. Sheba is a true hospital without borders, welcoming patients and medical professionals from all over the world and consistently providing the highest medical care to all who need it. Sheba has been ranked among the top 10 hospitals in the world by Newsweek three years in a row (2019, 2020, 2021).
About Biomica Ltd. :
Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapies using a dedicated computational predictive biology (CPB) platform, licensed from Evogene. Biomica aims to identify and characterize microbiome entities linked to disease and to develop new therapies based on this knowledge. The Company is focused on developing therapies for antibiotic-resistant bacteria, immuno-oncology and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, visit www.biomicamed.com.
About Evogene Ltd. :
Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational biology company that aims to revolutionize life science-based product development by using advanced technologies to increase the likelihood of success while reducing time and expense. development costs. Evogene has established three unique technology engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging big data and artificial intelligence and incorporating a deep multidisciplinary understanding of life sciences. Each technology engine is focused on the discovery and development of products based on one of the following building blocks: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetics (GeneRator AI). Evogene uses its technology engines to develop products through subsidiaries and with strategic partners. Currently, major Evogene subsidiaries are using the technology drivers to develop human microbiome-based therapies by Biomica Ltd., medical cannabis products by Canonic Ltd., agricultural chemicals by AgPlenus, and agricultural biologics by Lavie Bio Ltd. For more information, please visit: www.evogene.com.
This press release contains “forward-looking statements” relating to future events. These statements can be identified by words such as “may”, “could”, “expect”, “intend”, “anticipate”, “plan”, “believe”, “planned”, ” esteem” or words of similar meaning. For example, Biomica and Evogene use forward-looking statements in this press release when discussing the potential benefits of working with Sheba, the efficacy and potential benefits of BMC 333 in the treatment of IBD, and the expectation of Biomica for begin BMC333 scale-up and manufacturing processes in 2022, with a view to producing a first clinical batch. These statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties that are difficult to predict, and are not guarantees of future performance. Accordingly, the actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including without limitation the risk factors contained in Evogene’s reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or undertaking to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections.
GK Investor Relations
E: [email protected]
Such. : +1 212 378 8040
 Newsweek 2022. Source: https://www.newsweek.com/worlds-best-hospitals-2022
 mayolink. Source: https://www.mayoclinic.org/medical-professionals/digestive-diseases/news/managing-refractory-ibd/mac-20430383
 Grandview Search. Source: https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026
Logo – https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg
SOURCE Biomica Ltd.